[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ global_colors_info=”{}”][et_pb_row _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.16″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.18.0″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” width=”93.2%” max_width=”800px” custom_margin=”|23px|17px|||” custom_padding=”|37px||||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_menu menu_id=”93″ active_link_color=”#21242A” _builder_version=”4.18.0″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/et_pb_menu][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”tps” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”30px||0px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.9″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
TPS\u00ae is a tumor activity marker designed to support prognosis, treatment monitoring, and patient follow-up across a wide range of epithelial cancers, including breast cancer, colorectal cancer, ovarian cancer, and prostate cancer.<\/p>\n
TPS\u00ae measures soluble fragments of cytokeratin 18, a structural protein expressed in epithelial cells and frequently over-expressed in cancer. During tumor growth and increased cell turnover, these fragments are released into the bloodstream, where they serve as a marker of tumor cell activity.<\/p>\n
This makes TPS\u00ae a valuable tool for:<\/p>\n
As a tumor activity marker, TPS\u00ae provides clinicians with earlier insights into disease progression compared with conventional tumor mass markers. By reflecting the biological activity of tumor cells, TPS\u00ae enables more dynamic monitoring of disease development.<\/p>\n
TPS\u00ae is particularly useful for:<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/immunotech.cz\/Search?q=tps” url_new_window=”on” button_text=”IRMA” _builder_version=”4.27.9″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/05\/tps.jpg” alt=”tps tumor activity marker” title_text=”tps” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
The TPS\u00ae ELISA assay is well established for monitoring epithelial cancers and is used to generate reliable information on tumor activity over time.<\/p>\n
Clinical studies demonstrate particular relevance in breast and prostate cancer, where the assay supports clinical decision-making during treatment. In addition, the method has shown value in other epithelial malignancies, such as colorectal and ovarian cancer.<\/p>\n
By reflecting changes in tumor cell activity, TPS\u00ae ELISA complements existing diagnostic tools and contributes to a more informed and individualized patient management approach.<\/p>\n
[\/et_pb_text][et_pb_toggle title=”References for TPS\u00ae” disabled_on=”off|off|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
TPS\u00ae\u202fgeneral<\/strong> 2.\u202fRydlander L., et al. Molecular characterization of a tissue-polypeptide specific antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem. 1996; 241: 309-314<\/a><\/p>\n TPS\u00ae\u202fin breast<\/strong> TPS\u00ae\u202fin prostate <\/strong> TPS\u00ae\u202fin ovarian <\/strong> [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”monototal” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.9″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n MonoTotal\u00ae is a quantitative immunoassay designed for the assessment of tumor activity in lung cancer, with a particular focus on Non-Small Cell Lung Cancer (NSCLC). It supports prognosis, treatment monitoring, and patient follow-up, providing clinically relevant insights throughout the disease course.<\/p>\n MonoTotal\u00ae measures soluble fragments of cytokeratin 19, 8, and 18, which are released into the bloodstream during tumor growth and increased cell turnover. The concentration of these cytokeratin fragments in serum is directly proportional to tumor cell activity, making MonoTotal\u00ae a reliable indicator of disease dynamics.<\/p>\n Elevated levels are associated with epithelial tumor activity, particularly in lung cancer, where changes in biomarker levels can reflect disease progression and treatment response.<\/p>\n Lung cancer is one of the most commonly diagnosed cancers and a leading cause of cancer-related mortality worldwide. Within lung cancer, NSCLC accounts for the majority of cases, highlighting the need for reliable biomarkers to support patient management.<\/p>\n As a tumor activity marker, MonoTotal\u00ae provides clinicians with early indications of disease status, enabling:<\/p>\n \u00a0Unlike conventional approaches that primarily assess tumor burden, MonoTotal\u00ae reflects real-time tumor cell activity, offering a more dynamic perspective on disease development.<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/monototal” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/couple-running.jpeg” title_text=”Cheerful active senior couple jogging in the park. Exercise together to stop aging.” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”0px|||||” global_colors_info=”{}”]<\/p>\n MonoTotal\u00ae has demonstrated a strong correlation with tumor cell activity and disease extent, making it a clinically relevant biomarker for evaluating lung cancer progression.<\/p>\n Published studies show that MonoTotal\u00ae is closely associated with clinical response in patients, supporting its role in treatment monitoring. The assay demonstrates high sensitivity in NSCLC, independent of histological subtype, which reinforces its applicability across different patient groups.<\/p>\n With an overall sensitivity of approximately 70\u201375% at 95% specificity, MonoTotal\u00ae provides a robust balance between sensitivity and specificity. This performance, combined with its ability to reflect tumor activity, makes MonoTotal\u00ae a reliable tool for assessing disease status and supporting clinical decision-making over time.<\/p>\n [\/et_pb_text][et_pb_toggle title=”References for MonoTotal\u00ae” disabled_on=”off|off|off” _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n 1.\u202fBarak, V. et al. Clinical utility of cytokeratin as a tumor marker. Clin Biochem. 2004;37:529-540.<\/a><\/p>\n 2. Eriksson, P. et al. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment. Neoplasma. 2006;53:285-290.<\/a><\/p>\n 3. Topolcan, O. et al. The importance of MonoTotal\u00ae\u202ffor primary diagnosis of patients with non-small cell lung cancer (NSCLC). Anticancer Res. 2008;28:4038-4039.<\/a><\/p>\n 4. Kim, DW. et al. Evaluation of usefulness for MonoTotal\u2122 in non-small cell lung cancer. J Nucl Med Tech. 2009;13:171-174.<\/p>\n 5. Wojcik, E. et al. Evaluation of the diagnostic utility of MonoTotal\u00ae\u202fin lung cancer patients. J Lab Diagn. 2009; 45:75-80.<\/p>\n 6. Topolcan, O. et al. (Abstract). MonoTotal\u00ae\u202f\u2013 prognosis and therapy control in patients with non small cell lung cancer (NSCLC). XIIth International Symposium on Biology and Clinical Usefulness of Tumor Markers, February 4-7, 2009, Barcelona, Spain.<\/p>\n 7. Prazakova, M. et al. The role of MonoTotal\u00ae\u202fin the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC) Anticancer Res. 2011;31:3107-3112.<\/a><\/p>\n [\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”ubc” _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.9″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n UBC\u00ae is a urine-based immunoassay designed for both primary diagnosis and monitoring of bladder cancer. By providing clinically relevant information from non-invasive urine samples, UBC\u00ae supports early detection, treatment monitoring, and patient follow-up.<\/p>\n UBC\u00ae measures soluble fragments of cytokeratin 8 and 18 in urine, proteins that are released during tumor growth and epithelial cell turnover. Elevated levels of these cytokeratin fragments are commonly found in patients with bladder cancer, including those in early stages of the disease.<\/p>\n As a urine-based biomarker, UBC\u00ae enables:<\/p>\n Bladder cancer is characterized by a high risk of recurrence, making effective monitoring essential for patient management. UBC\u00ae provides clinicians with a reliable tool for assessing tumor activity over time, complementing standard diagnostic procedures.<\/p>\n UBC\u00ae is particularly useful for:<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_button button_url=”http:\/\/immunotech.cz\/ubc-elisa” url_new_window=”on” button_text=”ELISA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”http:\/\/immunotech.cz\/UBC” url_new_window=”on” button_text=”IRMA” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/05\/UBC-scaled.jpg” title_text=”UBC” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.27.9″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n The UBC\u00ae assay is a valuable tumor marker for epithelial cancers, providing clinically relevant information specifically in bladder cancer management.<\/p>\n Its ability to generate measurable data from urine samples supports clinicians in evaluating disease presence and progression, contributing to more informed and timely clinical decision-making. As part of a broader diagnostic strategy, UBC\u00ae enhances the ability to monitor patients consistently over time, particularly in settings where early detection and recurrence monitoring are critical.<\/p>\n <\/p>\n [\/et_pb_text][et_pb_toggle title=”References” disabled_on=”off|off|off” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n 1. Mian, C., et al. Comparison of two qualitative assays, the UBC Rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urol 2000; 56: 228-231.<\/a><\/p>\n 2. Sil\u00e9n, \u00c5., et al. Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer. Oncol Rep 2000; 7: 1269-1274.<\/a><\/p>\n 3. Sumi, S., et al. Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2000; 296:111-120.<\/a><\/p>\n 4. S\u00e1nchez-Carbayo, M. et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, Cyfra 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165:1462-1467.<\/a><\/p>\n
1.\u202fBarak V., et al. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004; 37:529-540<\/a><\/p>\n
3. \u202fAhn S.K., et al. Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast <\/a>cancer. Int J Cancer. 2013; 132:875-881\u00a0<\/a><\/p>\n
4. Kil P.J., et al. Tissue polypeptide specific (TPS) determination before and during intermittant maximal androgen blockade in patients with prostatic carcinoma. Euro Urol. 2003; 43:31-38<\/p>\n
5. Van Dalen A., et al. Significance of serum CA125 and TPS antigen levels for detemination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaec Oncol. 2009; 30:609-615<\/p>\nMonoTotal\u00ae<\/h6>\n
High sensitivity for Non-Small Cell Lung Cancer (NSCLC)<\/h3>\n
What does MonoTotal\u00ae measure?<\/h3>\n
What is the clinical value of MonoTotal\u00ae in lung cancer management?<\/h3>\n
\n
Find more information<\/h3>\n
Clinical Evaluation of MonoTotal\u00ae in NSCLC<\/h3>\n
UBC\u00ae<\/h6>\n
Urine-based detection of bladder cancer using UBC\u00ae<\/h3>\n
What does UBC\u00ae measure?<\/h3>\n
\n
What is the clinical value of UBC\u00ae in bladder cancer management?<\/h3>\n
\n
<\/h4>\n
Find more information\u00a0<\/h3>\n
Clinical Evaluation of UBC\u00ae in Bladder Cancer<\/h3>\n